Laszlo Radvanyi | President and Scientific Director
Ontario Institute for Cancer Research

Laszlo Radvanyi, President and Scientific Director, Ontario Institute for Cancer Research

Dr. Laszlo Radvanyi earned his Ph.D. degree in Clinical Biochemistry in 1996 at the University of Toronto, Toronto, Canada specializing in Immunology. Laszlo is currently the President and Scientific Director of the Ontario Institute for Cancer Research (OICR) in Toronto, Canada, overseeing all research activities of the institute across Ontario. The OICR ( supports both basic and translational research in oncology across Ontario and serves as catalyst facilitating the commercialization of promising research discoveries in Ontario.
Prior to this, Laszlo was a Senior Vice President in R&D at EMD Serono (Merck KGaA, Darmstadt, Germany), joining the company as Global Head of the Immuno-Oncology (IO) Translational Innovation Platform (TIP) in November 2015. At EMD Serono, Laszlo rebuilt and re-organized immuno-oncology research hiring key talent, restructuring the organization, and re-focusing the IO pipeline. Prior to joining EMD Serono, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center (MDACC) in Houston for 10 years. He ran a cell therapy manufacturing program for clinical trials of expanded tumor-infiltrating lymphocytes (TIL) and performed basic research on TIL biology and also ran an Immunomonitoring Core Facility. Laszlo was then the founding CSO of Iovance Therapeutics commercializing TIL therapy for melanoma and other cancers. Laszlo has authored over 120 published papers and book chapters, has served on the advisory boards of pharmaceutical and biotech companies and has sat on a number of national and international research grant review panels, including US, Canadian, and European agencies. He is on the Keystone Conferences Scientific Advisory Board, is an Associate Editor for the Journal of Immunotherapy for Cancer (JITC) and sits on the Industry Advisory Council of the Society for Immunotherapy of Cancer (SITC).


Festival of Biologics Day 1 @ 10:00

Current status and future prospects of cancer

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers